Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292105 | 0.85 | ALDH3A1 (0.61) | ALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL21208571 | 0.74 | PKM (0.38) | IDO1 | |
| SCHEMBL12227994 | 0.73 | ALDH1A1 (0.55) | ALDH1A1ALDH3A1ALDH1A3IDO1HPGD | |
| SCHEMBL16731702 | 0.73 | ALDH1A3 (0.46) | ALDH1A1ALDH3A1ALDH1A3GAA | |
| SCHEMBL19594987 | 0.72 | ALDH1A1 (0.50) | ALDH1A1ALDH3A1ALDH1A3HPGDMEN1 | |
| SCHEMBL6185779 | 0.72 | ALDH1A1 (0.45) | ALDH1A1ALDH3A1ALDH1A3GAA | |
| SCHEMBL9798478 | 0.71 | ALDH3A1 (0.56) | ALDH1A1ALDH3A1ALDH1A3HPGD | |
| SCHEMBL11799852 | 0.70 | GAA (0.38) | ALDH1A1GAAHTTMEN1KMT2A | |
| SCHEMBL14701207 | 0.70 | DNM1 (0.51) | ALDH1A1HTTHPGDMEN1KMT2A | |
| SCHEMBL5860513 | 0.69 | KDM4E (0.41) | ALDH1A1GAAHTTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534676-B1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-7985760-B2 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-26 | — | — | US | disclosed |
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | OXFORD GLYCOSCIENCES(UK) LTD (GB) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | CERS2, UGCG, GBA1 | ALDH1A1 894/4885ALDH3A1 558/4885ALDH1A3 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.